ROCKET PHARMACEUTICALS, INC.

During the six months ended June 30, 2026, operating activities used $85.0 million of cash and cash equivalents, primarily resulting from reduction of our net income of $75.6 million by the gain on sale of PRV of $178.2 million and changes in operating assets and liabilities of, net, $0.9 million. These were reduced by net non-cash charges of $18.5 million, including non-cash stock-based compensation expense of $15.9 million, depreciation and amortization expense of $4.2 million, partially offset by accretion of discount on investments of $1.7 million. Changes in our operating assets and liabilities for the six months ended June 30, 2026 included a increase in accounts payable and accrued expenses of $1.1 million and an increase in our prepaid expenses of $2.0 million.

During the six months ended June 30, 2025, operating activities used $104.8 million of cash and cash equivalents, primarily resulting from our net loss of $130.3 million offset by net non-cash charges of $22.5 million, including non-cash stock-based compensation expense of $21.2 million, depreciation and amortization expense of $5.6 million, partially offset by accretion of discount on investments of $4.3 million. Changes in our operating assets and liabilities for the six months ended June 30, 2025, included an increase in accounts payable and accrued expenses of $2.9 million and a decrease in our prepaid expenses of $0.2 million.